TrialSafety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Trial details
- Registry ID
- NCT04091646
- Phase
- Phase 2
ARQT
Arcutis Biotherapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
13Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceOpen-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Trial details
- Registry ID
- NCT04286607
- Phase
- Phase 3
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Trial details
- Registry ID
- NCT04445987
- Phase
- Phase 2
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Trial details
- Registry ID
- NCT04655313
- Phase
- Phase 2
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
Trial details
- Registry ID
- NCT04746911
- Phase
- Phase 2
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial details
- Registry ID
- NCT04773587
- Phase
- Phase 3
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Trial details
- Registry ID
- NCT04773600
- Phase
- Phase 3
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial details
- Registry ID
- NCT04804605
- Phase
- Phase 3
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
Trial details
- Registry ID
- NCT04811131
- Phase
- Phase 2
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Trial details
- Registry ID
- NCT04845620
- Phase
- Phase 3
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Trial details
- Registry ID
- NCT04973228
- Phase
- Phase 3
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Trial details
- Registry ID
- NCT05028582
- Phase
- Phase 3
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Trial details
- Registry ID
- NCT06998056
- Phase
- Phase 2
Latest recorded trial changes
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
NCT04286607 · Arcutis Biotherapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Occurrence of treatment emergent AEs (TEAEs)
+ Updated value
measure: Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs); measure: Percentage of Participants With ≥1 Serious Adverse Events (SAEs)
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count
Recorded edit− Previous value
count: 333; type: ACTUAL
+ Updated value
count: 337; type: ACTUAL
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
NCT04746911 · Arcutis Biotherapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite; measure: Incidence of adverse events; measure: Incidence of application site reactions
+ Updated value
measure: Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3%; measure: Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3%; measure: Number of Participants With an Adverse Event (AE); measure: Number of Participants With Application Site Reactions
The saved outcome text may be shortened. Check the source for full wording.
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
NCT06998056 · Arcutis Biotherapeutics, Inc.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 100; type: ESTIMATED
+ Updated value
count: 101; type: ACTUAL
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2026-06
+ Updated value
2025-12-04
Recruitment status
Recorded edit− Previous value
Recruiting
+ Updated value
Completed
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
NCT04845620 · Arcutis Biotherapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline at Week 4.
+ Updated value
measure: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
The saved outcome text may be shortened. Check the source for full wording.
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
NCT04804605 · Arcutis Biotherapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: To assess long-term safety in a multicenter, open-label, single-arm, 52-week study in subjects with atopic dermatitis treated with ARQ-151 cream: AEs and SAEs
+ Updated value
measure: Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE)
The saved outcome text may be shortened. Check the source for full wording.